Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth.
ADP-Ribosylation Factors
/ antagonists & inhibitors
Adult
Animals
Cell Line, Tumor
Cell Proliferation
/ drug effects
Gene Expression Regulation, Neoplastic
Humans
Liver
/ drug effects
Liver Neoplasms
/ drug therapy
Mice
Neoplasm Metastasis
Oligonucleotides, Antisense
/ genetics
RNA, Small Interfering
/ genetics
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
26
07
2018
revised:
26
10
2018
accepted:
10
01
2019
pubmed:
17
1
2019
medline:
13
3
2020
entrez:
17
1
2019
Statut:
ppublish
Résumé
ADP-ribosylation factor-like 4c (ARL4C) is identified as a small GTP-binding protein, which is expressed by Wnt and EGF signaling and plays an important role in tubulogenesis of cultured cells and the ureters. ARL4C is little expressed in adult tissues, but it is highly expressed in lung cancer and colorectal cancer and shown to represent a molecular target for cancer therapy based on siRNA experiments. This study revealed that ARL4C is highly expressed in primary hepatocellular carcinoma (HCC) tumors and colorectal cancer liver metastases, and that ARL4C expression is associated with poor prognosis for these cancers. Chemically modified antisense oligonucleotides (ASO) against ARL4C effectively reduced ARL4C expression in both HCC and colorectal cancer cells and inhibited proliferation and migration of these cancer cells
Identifiants
pubmed: 30647122
pii: 1535-7163.MCT-18-0824
doi: 10.1158/1535-7163.MCT-18-0824
doi:
Substances chimiques
Oligonucleotides, Antisense
0
RNA, Small Interfering
0
ADP-Ribosylation Factors
EC 3.6.5.2
ARL4C protein, human
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
602-612Informations de copyright
©2019 American Association for Cancer Research.